Jeffrey Tong, Ph.D.
Jeff Tong joined Third Rock in 2016, and focuses on drug discovery and development across the portfolio. He brings significant operational experience in building and growing early stage biotechnology companies. His portfolio company roles include:
- Chairman of the board and former interim chief executive officer of Ambys Medicines
- Board member of Maze Therapeutics
- Board member of Nurix
Prior to joining Third Rock, Jeff was Executive Chairman of the Board of Delinia, a company developing novel therapeutics for the treatment of autoimmune diseases. From 2010 to 2015, Jeff was the President and Chief Executive Officer of Nora Therapeutics. Prior to that, he was a member of the founding management team at Infinity Pharmaceuticals where he led its corporate as well as product development activities. Over the course of his career, he has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through Phase 3 development, and developed integrated science/business strategies for the building of innovative biotechnology companies. Earlier in his career, he worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research. Jeff received his educational training at the interface of molecular biology, organic chemistry and medicine and holds A.B. and M.M.S. degrees from Harvard College and Harvard Medical School, respectively, as well as A.M. and Ph.D. degrees from Harvard University.
Jeff’s most memorable experience in biotech is taking a team to Idaho to dig up a plant that contained a chemical precursor for an anticancer drug and then driving a giant U-Haul truck full of this back to a group of waiting medicinal chemists.